F/M Investments’s Keros Therapeutics KROS Stock Holding History

F/M Investments’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-17,061	Closed	-$270K	–	401
2024 Q4	$270K	Buy	+17,061	New	+$887K	0.01%	370

Other funds holding KROS

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

F/M Investments's KROS Position: Q1 2025 in Review

F/M Investments sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 17,061 shares — an estimated $270K sold.

F/M Investments first reported a position in KROS in Q4 2024 and held it in 1 quarter. The position peaked at $270K in Q4 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

F/M Investments reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
F/M Investments sold 17,061 Keros Therapeutics shares in Q1 2025, an estimated $270K.
F/M Investments first reported a position in Keros Therapeutics in Q4 2024 and held it in 1 quarter.
F/M Investments's Keros Therapeutics position peaked at $270K in Q4 2024.
156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on F/M Investments's 13F filing for Q1 2025, filed 14 May 2025.